Skip to contentA
Acro Biomedical Co., Ltd.
A
ACBMAcro Biomedical Co., Ltd. Q3 2021 · 10-Q
Revenue$0.00$0.00— vs Q3 2020 Net Income-$2.99M-$2.99MN/M vs Q3 2020 EPS Diluted-$0.05-$0.05— vs Q3 2020 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Acro Biomedical Co., Ltd. · CIK 1622996 · Engraved from SEC EDGAR
-$2,990,656
N/M
Operating Cash Flowderived-$64,549N/M ended Sep 30, 2021 · filed Nov 22, 2021 · 53 d after period end